319 related articles for article (PubMed ID: 26835979)
1. Irinotecan Delivery by Lipid-Coated Mesoporous Silica Nanoparticles Shows Improved Efficacy and Safety over Liposomes for Pancreatic Cancer.
Liu X; Situ A; Kang Y; Villabroza KR; Liao Y; Chang CH; Donahue T; Nel AE; Meng H
ACS Nano; 2016 Feb; 10(2):2702-15. PubMed ID: 26835979
[TBL] [Abstract][Full Text] [Related]
2. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice.
Meng H; Wang M; Liu H; Liu X; Situ A; Wu B; Ji Z; Chang CH; Nel AE
ACS Nano; 2015; 9(4):3540-57. PubMed ID: 25776964
[TBL] [Abstract][Full Text] [Related]
3. Improved Efficacy and Reduced Toxicity Using a Custom-Designed Irinotecan-Delivering Silicasome for Orthotopic Colon Cancer.
Liu X; Jiang J; Chan R; Ji Y; Lu J; Liao YP; Okene M; Lin J; Lin P; Chang CH; Wang X; Tang I; Zheng E; Qiu W; Wainberg ZA; Nel AE; Meng H
ACS Nano; 2019 Jan; 13(1):38-53. PubMed ID: 30525443
[TBL] [Abstract][Full Text] [Related]
4. Lipid-based mesoporous silica nanoparticles: a paradigm shift in management of pancreatic cancer.
Bellapu KK; Joga R; Kannan BR; Yerram S; Varpe P; Mergu T; Vasu PY; Srivastava S; Kumar S
Pharm Pat Anal; 2023 Nov; 12(6):261-273. PubMed ID: 38214201
[TBL] [Abstract][Full Text] [Related]
5. [Antitumor efficacy of irinotecan-loaded galactosyl modified lipid bilayer-coated mesoporous silica nanoparticles against hepatocellular carcinoma cells].
Chen X; Zhang XX; Li FF; Zhao YN; Jia Z; Gan Y; Li J
Yao Xue Xue Bao; 2014 May; 49(5):718-25. PubMed ID: 25151746
[TBL] [Abstract][Full Text] [Related]
6. [Preliminary study on pH-sensitive lipid bilayer-coated mesoporous silica nanoparticles as a novel drug carrier for antitumor drug].
Li FF; Zhang XX; Guo SY; Gan Y; Li J
Yao Xue Xue Bao; 2013 Feb; 48(2):291-7. PubMed ID: 23672029
[TBL] [Abstract][Full Text] [Related]
7. Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer.
Ur Rehman SS; Lim K; Wang-Gillam A
Expert Rev Anticancer Ther; 2016 May; 16(5):485-92. PubMed ID: 27043737
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Modified FOLFIRINOX for Advanced Pancreatic Adenocarcinoma: A UK Single-Centre Experience.
Ghorani E; Wong HH; Hewitt C; Calder J; Corrie P; Basu B
Oncology; 2015; 89(5):281-7. PubMed ID: 26372905
[TBL] [Abstract][Full Text] [Related]
9. Two-wave nanotherapy to target the stroma and optimize gemcitabine delivery to a human pancreatic cancer model in mice.
Meng H; Zhao Y; Dong J; Xue M; Lin YS; Ji Z; Mai WX; Zhang H; Chang CH; Brinker CJ; Zink JI; Nel AE
ACS Nano; 2013 Nov; 7(11):10048-65. PubMed ID: 24143858
[TBL] [Abstract][Full Text] [Related]
10. Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities.
Waterhouse DN; Sutherland BW; Santos ND; Masin D; Osooly M; Strutt D; Ostlund C; Anantha M; Harasym N; Manisali I; Wehbe M; Bally MB; Webb MS
Invest New Drugs; 2014 Dec; 32(6):1071-82. PubMed ID: 25064374
[TBL] [Abstract][Full Text] [Related]
11. Iontophoretic device delivery for the localized treatment of pancreatic ductal adenocarcinoma.
Byrne JD; Jajja MR; Schorzman AN; Keeler AW; Luft JC; Zamboni WC; DeSimone JM; Yeh JJ
Proc Natl Acad Sci U S A; 2016 Feb; 113(8):2200-5. PubMed ID: 26858448
[TBL] [Abstract][Full Text] [Related]
12. Mesoporous silica nanoparticle nanocarriers: biofunctionality and biocompatibility.
Tarn D; Ashley CE; Xue M; Carnes EC; Zink JI; Brinker CJ
Acc Chem Res; 2013 Mar; 46(3):792-801. PubMed ID: 23387478
[TBL] [Abstract][Full Text] [Related]
13. Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma.
Mahaseth H; Brutcher E; Kauh J; Hawk N; Kim S; Chen Z; Kooby DA; Maithel SK; Landry J; El-Rayes BF
Pancreas; 2013 Nov; 42(8):1311-5. PubMed ID: 24152956
[TBL] [Abstract][Full Text] [Related]
14. Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer.
Liu X; Lin P; Perrett I; Lin J; Liao YP; Chang CH; Jiang J; Wu N; Donahue T; Wainberg Z; Nel AE; Meng H
J Clin Invest; 2017 May; 127(5):2007-2018. PubMed ID: 28414297
[TBL] [Abstract][Full Text] [Related]
15. Nanocarrier Co-formulation for Delivery of a TLR7 Agonist plus an Immunogenic Cell Death Stimulus Triggers Effective Pancreatic Cancer Chemo-immunotherapy.
Luo L; Wang X; Liao YP; Chang CH; Nel AE
ACS Nano; 2022 Aug; 16(8):13168-13182. PubMed ID: 35920660
[TBL] [Abstract][Full Text] [Related]
16. Irinotecan (Campto) in the treatment of pancreatic cancer.
Pizzolato JF; Saltz LB
Expert Rev Anticancer Ther; 2003 Oct; 3(5):587-93. PubMed ID: 14599083
[TBL] [Abstract][Full Text] [Related]
17. Photodynamic Therapy Synergizes with Irinotecan to Overcome Compensatory Mechanisms and Improve Treatment Outcomes in Pancreatic Cancer.
Huang HC; Mallidi S; Liu J; Chiang CT; Mai Z; Goldschmidt R; Ebrahim-Zadeh N; Rizvi I; Hasan T
Cancer Res; 2016 Mar; 76(5):1066-77. PubMed ID: 26719532
[TBL] [Abstract][Full Text] [Related]
18. Sphingomyelin Liposomes Containing Porphyrin-phospholipid for Irinotecan Chemophototherapy.
Carter KA; Luo D; Razi A; Geng J; Shao S; Ortega J; Lovell JF
Theranostics; 2016; 6(13):2329-2336. PubMed ID: 27877238
[TBL] [Abstract][Full Text] [Related]
19. Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan.
Ko AH
Int J Nanomedicine; 2016; 11():1225-35. PubMed ID: 27099488
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of docetaxel-irinotecan combination in advanced pancreatic cancer.
Kurtz JE; Négrier S; Husseini F; Limacher JM; Borel C; Wagner JP; Prévot G; Bergerat JP; Dufour P
Hepatogastroenterology; 2003; 50(50):567-70. PubMed ID: 12749274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
